Accuray Incorporated ARAY

The agreements bring together mobile CT capabilities and precision treatment delivery expertise to improve anatomical visualisation during radiotherapy.

Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System. The announcement coincides with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray's strategy to add

Accuray Inc.’s (NASDAQ:ARAY) recent agreement with RaySearch Laboratories around an extended alliance, is a major step toward online adaptive radiation therapy. The integration of Accuray’s imaging technology and photon-based radiation therapy platforms with RaySearch’s proprietary planning and workflow solutions, will fast-track innovation across the space. For Accuray, the arrangement will also accelerate its adoption to […]

Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.

On August 19, Accuray Incorporated (NASDAQ:ARAY) held its fiscal fourth-quarter and full-year 2026 earnings call, laying out a business caught between a genuine financial rescue and a China market that is still bleeding revenue. Total net revenue fell 21% in the quarter to $100.9 million, and the company won’t even offer a forecast for the […]

Accuray exceeds cost-saving targets and strengthens balance sheet through TCW deal, despite revenue headwinds from China and tariff pressures.

Moby summary of Accuray Incorporated's Q4 2026 earnings call

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.

Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth.

Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2026, ended June 30, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on August 19, 2026.

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index falling 1.7% and the S

Accuray (ARAY) said late Wednesday it has entered into definitive agreements with TCW Asset Manageme

Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced a plan incorporating several decisive actions that will drive a significant improvement in its financial position, a fundamental change in its business strategy, the rollout of differentiated technology, and continued transformation in how the company operates. This enables a renewed focus on its core strengths in innovation, sales, and service while continuing to emphasize

The latest update on Accuray centers on a sharp reset in its fair value estimate, with the target reduced from US$3.88 to US$0.35. Analysts are reworking their models to reflect more cautious assumptions, and that shift is feeding directly into revised price targets and a recalibrated narrative around what is realistic for the stock. As you read on, you will see how these changing views are taking shape and what to watch to stay on top of the evolving story around Accuray. Analyst Price...

Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10‑year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newe

Accuray Inc (NASDAQ:ARAY) is one of the best small cap robotics stocks to buy according to analysts. The March quarter results that Accuray Inc (NASDAQ:ARAY) reported on May 6 showed the company’s revenue decreased, and the loss widened. The company revealed problems in its Middle East market, citing geopolitical uncertainties. It said the Middle East […]

The recent 17% drop in Accuray Incorporated's ( NASDAQ:ARAY ) stock could come as a blow to insiders who purchased...